Clinical trials
Relapsed or Refractory Plasma Cell Neoplasms clinical trials
Below are recruiting relapsed or refractory plasma cell neoplasms clinical trials, each written for real people, not researchers. We’re tracking 1,649 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT05101551RecruitingPhase 1
Talazoparib with chemotherapy for relapsed childhood AML
This Phase 1 study tests whether talazoparib combined with chemotherapy is safe and potentially effective for children and young adults whose leukemia has come back or did not respond. It focuses on finding the best way to give the treatment and watching for side effects.
Phoenix, ArizonaAges Up to 21 years - NCT05057702Recruiting
Personalized surgery-focused treatment plan for relapsed brain cancer
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
Los Angeles, CaliforniaAges 1–39 - NCT05019703RecruitingPhase 2
Atezolizumab plus cabozantinib for teen osteosarcoma
This trial studies a combination of two medicines—atezolizumab and cabozantinib—for teenagers and young adults with osteosarcoma that has come back or spread. It aims to slow or shrink the cancer and help control disease that can’t be fully removed with surgery.
Boston, MassachusettsAges 12 years+ - NCT05041140Recruiting
Xenon MRI test for lung problems after stem cell transplant
This study uses a special MRI test with xenon gas to look at lung function in adults who had a stem cell transplant and now have breathing-related complications. It may help doctors measure lung impairment more clearly and track changes over time.
Houston, TexasAges 18 years+ - NCT05011266RecruitingPhase 2/Phase 3
Buprenorphine plus naltrexone shot to prevent opioid relapse
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
Rockville, MarylandAges 18–65 - NCT04959175RecruitingPhase 1/Phase 2
Lower-dose transplant drug for older or frail patients with blood cancer
This study tests whether a lower dose of a drug used after bone marrow transplant can reduce side effects while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). It is for older patients or those who are not healthy enough for a standard, stronger conditioning regimen.
Bethesda, MarylandAges 12–85 - NCT04972760RecruitingPhase 3
Baricitinib for active dermatomyositis in adults
This trial studies whether baricitinib can improve symptoms and test results in adults with active dermatomyositis (a muscle and skin inflammation disease). It’s for people whose disease is still active despite prior treatment or who have been recently diagnosed.
ParisAges 18–64 - NCT04990102RecruitingPhase 1/Phase 2
Trial drug to help prevent relapse in AML
This trial tests CPX-351 to help stop acute myeloid leukemia (AML) from coming back after you’ve reached remission. It’s for people who are not able to receive a stem cell transplant and need a new way to reduce relapse risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04928677RecruitingPhase 1
Codrituzumab for children and young adults with GPC3-positive solid tumors
This Phase 1 study tests codrituzumab, an antibody medicine, in children and young adults whose solid tumor has come back or did not respond to standard treatment. It’s designed to see how the treatment works and how safe it is, especially for tumors that test positive for GPC3.
Los Angeles, CaliforniaAges 1–21 - NCT04838041RecruitingPhase 2
Testing stopping treatment after asciminib for CML relapse
This trial looks at whether people with chronic-phase CML who tried stopping a prior CML medicine and had to restart can later stop treatment again after a set period using asciminib. It checks whether you can stay in a deep remission (“free remission” without the usual CML tablets).
Detroit, MichiganAges 18 years+ - NCT04783857RecruitingPhase 4
Hormone therapy to prevent smoking relapse after childbirth
This trial tests whether giving progesterone after childbirth can help new mothers stay quit from smoking, reducing secondhand smoke exposure to their babies. It's for women who smoked before pregnancy and want to remain smoke-free after delivery.
Minneapolis, MinnesotaAges 18–45 - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT04844866RecruitingPhase 2
CAR T-cell treatment versus standard care for relapsed lymphoma
This trial tests a CAR T-cell therapy (MB-CART2019.1) against standard treatment in people with certain types of aggressive B-cell lymphoma that has come back or didn’t respond to the first treatment. It aims to improve how well the lymphoma responds and to check for side effects and safety.
GrazAges 18–70 - NCT04696029RecruitingPhase 2
DFMO to prevent return of high-risk or relapsed medulloblastoma
This Phase 2 study tests DFMO (a maintenance medicine) to help stop medulloblastoma from coming back or worsening after prior treatment. It focuses on children and young people with specific high-risk tumor types or tumors that have returned or not responded well to treatment.
Little Rock, ArkansasAges Up to 21 years - NCT04708054RecruitingPhase 2/Phase 3
Venetoclax with busulfan chemo for high-risk AML or MDS
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
Houston, TexasAges 18–70 - NCT04511013RecruitingPhase 2
Trial for BRAF-mutant melanoma spread to the brain
This Phase 2 study tests whether a 3-drug plan (encorafenib + binimetinib + nivolumab) works better than ipilimumab + nivolumab for melanoma that has spread to the brain. If you qualify, you’ll get either treatment and have frequent brain scans to track how well it controls the tumors.
Birmingham, AlabamaAges 18 years+ - NCT04561206RecruitingPhase 2
Brentuximab plus nivolumab for relapsed Hodgkin lymphoma
This Phase 2 trial studies brentuximab vedotin plus nivolumab in people whose classical Hodgkin lymphoma has come back or did not respond to treatment. It aims to shrink tumors and improve control of the disease, especially when standard options like transplant are not possible.
Duarte, CaliforniaAges 18 years+ - NCT04483206RecruitingPhase 1
Personalized stem cell transplant for multiple myeloma
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Atlanta, GeorgiaAges 18 years+ - NCT04480853RecruitingPhase 4
Fingolimod start study for adults with relapsing MS
This study checks how safe and effective fingolimod is when adults with relapsing-remitting multiple sclerosis start it for the first time. It may help confirm whether this treatment works well and is tolerated in newly treated patients.
Kaohsiung CityAges 20–100 - NCT04322318RecruitingPhase 2
Study of combination chemotherapy for Wilms tumor in children
This Phase 2 trial tests combination chemotherapy for children with certain types of Wilms tumor—either newly diagnosed diffuse anaplastic Wilms tumor or favorable Wilms tumor that has come back. The goal is to see how well the treatment controls the tumor and is tolerable for children.
Birmingham, AlabamaAges Up to 30 years - NCT04308330RecruitingPhase 1
Vorinostat plus chemotherapy for advanced tumors in brain
This Phase 1 trial studies how safe and tolerable vorinostat is when combined with chemotherapy for cancers that have come back or are hard to treat, including tumors in the brain or spinal cord. It may help doctors find a better way to treat advanced solid tumors and CNS (brain/spinal cord) cancers.
Valhalla, New YorkAges 1–30 - NCT04373473RecruitingPhase 2
Oral stool treatment to prevent ulcerative colitis flare-ups
This study tests whether taking freeze-dried (lyophilized) donor stool material by mouth can help prevent ulcerative colitis from coming back or causing intestinal inflammation. Participants are in remission and stay on their usual treatment while receiving the study product.
Houston, TexasAges 18 years+ - NCT04318678RecruitingPhase 1
CD123 CAR T-cell therapy for relapsed leukemia and related cancers
This early-phase study tests a lab-made immune therapy (CD123 CAR T cells) for children and young adults up to age 21 whose cancer has come back or didn’t respond to treatment. The goal is to see if these CAR T cells can find and attack cancer cells that carry a marker called CD123.
Memphis, TennesseeAges Up to 21 years
Hear when a new Relapsed or Refractory Plasma Cell Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory plasma cell neoplasms?
- Yes. Clin2 currently lists 1,649 recruiting relapsed or refractory plasma cell neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory plasma cell neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory plasma cell neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
- Refractory Plasma Cell Myeloma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Multiple Myeloma and Malignant Plasma Cell Neoplasms
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.